Physician profile
David A Orr
NPI 1215016217
$14,140.05
in general payments reported to CMS, 2019-2025
39 companies · $3,179 in 2025
The $3,179 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $817 · 2021: $671 · 2022: $1,624 · 2023: $2,684 · 2024: $2,970 · 2025: $3,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,579 · Education: $212 · Consulting Fee: $42.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,579.09 |
| Education | $212.13 |
| Consulting Fee | $42.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,443.89 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,752.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,301.18 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Amgen INC. | $699.31 | 2021-2025 | Tezspire |
| Mylan Specialty L.P. | $575.54 | 2019-2024 | Yupelri |
| Genzyme Corporation | $561.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $561.22 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $525.95 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Actelion Pharmaceuticals US, INC. | $430.23 | 2019-2025 | Opsumit, Uptravi |
| Philips North America LLC | $334.15 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Genentech USA, INC. | $321.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $258.85 | 2019-2024 | |
| Viatris Specialty LLC | $225.54 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $195.77 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $190.61 | 2019-2025 | Keytruda, Winrevair |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $178.30 | 2023-2025 | Acthar |
| Insmed, INC. | $174.42 | 2020-2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $148.62 | 2019-2020 | |
| Harmony Biosciences LLC | $148.01 | 2023-2025 | Wakix |
| United Therapeutics Corporation | $141.34 | 2019-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $140.43 | 2020-2025 | Glassia, Aralast |
| Teva Pharmaceuticals USA, INC. | $120.93 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $93.51 | 2022-2025 | Purified Cortrophin Gel |
| Intuitive Surgical, INC. | $89.18 | 2024 | |
| Pulmonx Corporation | $66.60 | 2020-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Bayer Healthcare Pharmaceuticals INC. | $54.02 | 2021-2025 | |
| Verona Pharma, INC. | $54.02 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $50.74 | 2025 | Lumryz |
| Pfizer INC. | $50.29 | 2019-2022 | |
| Adma Biomanufacturing LLC | $42.26 | 2025 | |
| Shire North American Group INC | $42.18 | 2019 | |
| Jazz Pharmaceuticals INC. | $30.56 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.16 | 2019-2020 | |
| Baxter Healthcare | $24.51 | 2023 | Hillrom - Life 2000 Ventilation System |
| Lilly USA, LLC | $21.89 | 2025 | Zepbound |
| Emd Serono, INC. | $16.95 | 2019 | |
| Axsome Therapeutics, INC. | $16.81 | 2023 | Sunosi |
| Vifor Pharma, INC. | $15.45 | 2025 | Zemaira |
| Optinose US, INC. | $14.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.